|Stage of funding:||Current|
|Therapeutic group:||Infectious Diseases|
Founded by a highly experienced management team, Atea Pharmaceuticals, Inc. is an emerging biopharmaceutical company which is engaged in the acquisition, discovery and development of novel antiviral therapeutics.
NovaDigm Therapeutics, a company developing innovative immuno-therapeutics and preventative vaccines for fungal and bacterial infections, today announced the publication of data from a Phase 2a study of its NDV-3A vaccine program in the journal Clinical Infectious Diseases. The data demonstrate that a single dose of NDV-3A with alum adjuvant was safe, well-tolerated, immunogenic and efficacious, leading to reduced recurrences of vaginitis in patients with recurrent vulvovaginal candidiasis (RVVC). NDV-3A is the company’s lead development candidate to potentially treat or prevent diseases caused by fungal and bacterial pathogens, including antimicrobial-resistant strains.
24 April 2018
19 April 2018
12 April 2018